{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["Dyskinesia", "Levodopa", "Nitric oxide", "Parkinson\u2019s disease"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "34940921", "DateCompleted": {"Year": "2022", "Month": "03", "Day": "16"}, "DateRevised": {"Year": "2022", "Month": "03", "Day": "16"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2021", "Month": "12", "Day": "23"}], "ELocationID": ["10.1007/s00702-021-02447-4"], "Journal": {"ISSN": "1435-1463", "JournalIssue": {"Volume": "129", "Issue": "1", "PubDate": {"Year": "2022", "Month": "Jan"}}, "Title": "Journal of neural transmission (Vienna, Austria : 1996)", "ISOAbbreviation": "J Neural Transm (Vienna)"}, "ArticleTitle": "Levodopa-induced dyskinesias in Parkinson's disease increase cerebrospinal fluid nitric oxide metabolites' levels.", "Pagination": {"StartPage": "55", "EndPage": "63", "MedlinePgn": "55-63"}, "Abstract": {"AbstractText": ["Levodopa-induced dyskinesia (LID) is a common complication of Parkinson's disease (PD) therapy. Nitric oxide in the central nervous system may have a role in its pathophysiology. The present work investigates plasma and CSF levels of nitric oxide metabolites nitrite and nitrate in patients with PD, LID, and healthy control. We measured plasma and CSF nitrite and nitrate levels in patients with PD with and without LID and in healthy controls. The levels of plasma and CSF nitrite and nitrate were measured by ozone-based chemiluminescence. Sixty-seven participants were enrolled. CSF nitrite levels in patients with PD and LID were higher than in patients with PD without LID and healthy controls. CSF/plasma ratio of nitrite was higher in patients with PD and LID than in patients with PD without LID. The CSF/plasma ratio of nitrite in patients with PD and LID was higher than 1, indicating an intrathecal production of NO in patients with this motor complication. There was an increase in nitrate levels of CSF and CSF/plasma ratio of nitrate in patients with PD and LID compared to the healthy controls. Sex, age at evaluation, disease duration, and levodopa equivalent daily doses, as well as processing and storage time, did not critically influence these results. The present study demonstrated an increase in nitrite and nitrate levels in the central nervous system of patients with PD and LID. This finding strengthens the role of NO on LID pathophysiology."], "CopyrightInformation": "\u00a9 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neurosciences and Behavioral Sciences, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Av. Bandeirantes 3900, Ribeir\u00e3o Pr\u00eato, SP, 14049-900, Brazil."}, {"Identifier": [], "Affiliation": "Laboratory of Experimental Neuropathology, Federal University of Par\u00e1, Bel\u00e9m, Brazil."}], "LastName": "Santos-Lobato", "ForeName": "Bruno L", "Initials": "BL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Basic and Oral Biology, Faculty of Odontology of Ribeir\u00e3o Preto, University of S\u00e3o Paulo, Ribeir\u00e3o Pr\u00eato, SP, Brazil."}], "LastName": "Bortolanza", "ForeName": "Mariza", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nursing School of Ribeir\u00e3o Preto, University of S\u00e3o Paulo, Ribeir\u00e3o Pr\u00eato, SP, Brazil."}], "LastName": "Pinheiro", "ForeName": "Lucas C\u00e9sar", "Initials": "LC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nursing School of Ribeir\u00e3o Preto, University of S\u00e3o Paulo, Ribeir\u00e3o Pr\u00eato, SP, Brazil."}], "LastName": "Batalh\u00e3o", "ForeName": "Marcelo E", "Initials": "ME"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neurosciences and Behavioral Sciences, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Av. Bandeirantes 3900, Ribeir\u00e3o Pr\u00eato, SP, 14049-900, Brazil."}], "LastName": "Pimentel", "ForeName": "\u00c2ngela V", "Initials": "\u00c2V"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nursing School of Ribeir\u00e3o Preto, University of S\u00e3o Paulo, Ribeir\u00e3o Pr\u00eato, SP, Brazil."}], "LastName": "Capellari-Carnio", "ForeName": "Evelin", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Basic and Oral Biology, Faculty of Odontology of Ribeir\u00e3o Preto, University of S\u00e3o Paulo, Ribeir\u00e3o Pr\u00eato, SP, Brazil."}], "LastName": "Del-Bel", "ForeName": "Elaine A", "Initials": "EA"}, {"Identifier": ["0000-0003-2402-2709"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neurosciences and Behavioral Sciences, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Av. Bandeirantes 3900, Ribeir\u00e3o Pr\u00eato, SP, 14049-900, Brazil. tumasv@rnp.fmrp.usp.br."}], "LastName": "Tumas", "ForeName": "Vitor", "Initials": "V"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Austria", "MedlineTA": "J Neural Transm (Vienna)", "NlmUniqueID": "9702341", "ISSNLinking": "0300-9564"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antiparkinson Agents"}, {"RegistryNumber": "31C4KY9ESH", "NameOfSubstance": "Nitric Oxide"}, {"RegistryNumber": "46627O600J", "NameOfSubstance": "Levodopa"}], "MeshHeadingList": [{"QualifierName": ["adverse effects"], "DescriptorName": "Antiparkinson Agents"}, {"QualifierName": [], "DescriptorName": "Dyskinesias"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Levodopa"}, {"QualifierName": [], "DescriptorName": "Nitric Oxide"}, {"QualifierName": [], "DescriptorName": "Parkinson Disease"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Andersson M, Hilbertson A, Cenci MA (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson\u2019s disease. Neurobiol Dis 6:461\u2013474. https://doi.org/10.1006/nbdi.1999.0259", "ArticleIdList": ["10.1006/nbdi.1999.0259", "10600402"]}, {"Citation": "B\u00f6ckelmann R, Wolf G, Ransmayr G, Riederer P (1994) NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson\u2019s disease putamen. J Neural Transm Park Dis Dement Sect 7:115\u2013121. https://doi.org/10.1007/BF02260966", "ArticleIdList": ["10.1007/BF02260966", "7536004"]}, {"Citation": "Boll M-C, Alcaraz-Zubeldia M, Montes S, Rios C (2008) Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 33:1717\u20131723. https://doi.org/10.1007/s11064-008-9610-3", "ArticleIdList": ["10.1007/s11064-008-9610-3", "18307039"]}, {"Citation": "Cristalli DO, Arnal N, Marra FA, Alaniz MJT, Marra CA (2012) Peripheral markers in neurodegenerative patients and their first-degree relatives. J Neurol Sci 314:48\u201356. https://doi.org/10.1016/j.jns.2011.11.001", "ArticleIdList": ["10.1016/j.jns.2011.11.001", "22113180"]}, {"Citation": "\u00c7ubuk\u00e7u HC, Yurtda\u015f M, Durak ZE, Ayta\u00e7 B, G\u00fcne\u015f HN, \u00c7okal BG, Yolda\u015f TK, Durak I (2016) Oxidative and nitrosative stress in serum of patients with Parkinson\u2019s disease. Neurol Sci 37:1793\u20131798. https://doi.org/10.1007/s10072-016-2663-1", "ArticleIdList": ["10.1007/s10072-016-2663-1", "27423450"]}, {"Citation": "Danilov AI, Andersson M, Bavand N, Wiklund NP, Olsson T, Brundin L (2003) Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. J Neuroimmunol 136:112\u2013118. https://doi.org/10.1016/s0165-5728(02)00464-2", "ArticleIdList": ["10.1016/s0165-5728(02)00464-2", "12620649"]}, {"Citation": "Del Bel EA, Guimar\u00e3es FS, Berm\u00fadez-Echeverry M, Gomes MZ, Schiaveto-de-Souza A, Padovan-Neto FE, Tumas V, Barion-Cavalcanti AP, Lazzarini M, Nucci-da-Silva LP, Paula-Souza D (2005) Role of nitric oxide on motor behavior. Cell Mol Neurobiol 25:371\u2013392. https://doi.org/10.1007/s10571-005-3065-8", "ArticleIdList": ["10.1007/s10571-005-3065-8", "16047547"]}, {"Citation": "Del-Bel E, Padovan-Neto FE, Bortolanza M, Tumas V, Aguiar AS Jr, Raisman-Vozari R, Prediger RD (2015) Nitric oxide, a new player in L-DOPA-induced dyskinesia? Front Biosci 7:168\u2013192. https://doi.org/10.2741/e726", "ArticleIdList": ["10.2741/e726"]}, {"Citation": "Del-Bel E, Bortolanza M, Dos-Santos-Pereira M, Bariotto K, Raisman-Vozari R (2016) l-DOPA-induced dyskinesia in Parkinson\u2019s disease: are neuroinflammation and astrocytes key elements? Synapse 70:479\u2013500. https://doi.org/10.1002/syn.21941", "ArticleIdList": ["10.1002/syn.21941", "27618286"]}, {"Citation": "Dorsey ER, Bloem BR (2018) The Parkinson pandemic\u2014a call to action. JAMA Neurol 75:9\u201310. https://doi.org/10.1001/jamaneurol.2017.3299", "ArticleIdList": ["10.1001/jamaneurol.2017.3299", "29131880"]}, {"Citation": "Eve DJ, Nisbet AP, Kingsbury AE, Hewson EL, Daniel SE, Lees AJ, Marsden CD, Foster OJ (1998) Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson\u2019s disease. Brain Res Mol Brain Res 63:62\u201371. https://doi.org/10.1016/s0169-328x(98)00259-9", "ArticleIdList": ["10.1016/s0169-328x(98)00259-9", "9838046"]}, {"Citation": "Farias CC, Maes M, Bonif\u00e1cio KL, Bortolasci CC, Nogueira AS, Brinholi FF, Matsumoto AK, Nascimento MA, Melo LB, Nixdorf SL, Lavado EL, Moreira EG, Barbosa DS (2016) Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson\u2019s disease and its progression: disease and staging biomarkers and new drug targets. Neurosci Lett 617:66\u201371. https://doi.org/10.1016/j.neulet.2016.02.011", "ArticleIdList": ["10.1016/j.neulet.2016.02.011", "26861200"]}, {"Citation": "Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N (2008a) Movement disorder society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129\u20132170. https://doi.org/10.1002/mds.22340", "ArticleIdList": ["10.1002/mds.22340"]}, {"Citation": "Goetz CG, Nutt JG, Stebbins GT (2008b) The unified dyskinesia rating scale: presentation and clinimetric profile. Mov Disord 23:2398\u20132403. https://doi.org/10.1002/mds.22341", "ArticleIdList": ["10.1002/mds.22341", "19025759"]}, {"Citation": "Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CG, Urkowitz A, Jaglin JA, Ge S (2013) Which dyskinesia scale best detects treatment response? Mov Disord 28:341\u2013346. https://doi.org/10.1002/mds.25321", "ArticleIdList": ["10.1002/mds.25321", "23390076"]}, {"Citation": "Haghikia A, Kayacelebi AA, Beckmann B, Hanff E, Gold R, Haghikia A, Tsikas D (2015) Serum and cerebrospinal fluid concentrations of homoarginine, arginine, asymmetric and symmetric dimethylarginine, nitrite and nitrate in patients with multiple sclerosis and neuromyelitis optica. Amino Acids 47:1837\u20131845. https://doi.org/10.1007/s00726-015-2015-0", "ArticleIdList": ["10.1007/s00726-015-2015-0", "26055922"]}, {"Citation": "Hendgen-Cotta U, Grau M, Rassaf T, Gharini P, Kelm M, Kleinbongard P (2008) Reductive gas-phase chemiluminescence and flow injection analysis for measurement of the nitric oxide pool in biological matrices. Methods Enzymol 441:295\u2013315. https://doi.org/10.1016/S0076-6879(08)01216-0", "ArticleIdList": ["10.1016/S0076-6879(08)01216-0", "18554541"]}, {"Citation": "Ikeda M, Sato I, Yuasa T, Miyatake T, Murota S (1995) Nitrite, nitrate and cGMP in the cerebrospinal fluid in degenerative neurologic diseases. J Neural Transm Gen Sect 100:263\u2013267. https://doi.org/10.1007/BF01276464", "ArticleIdList": ["10.1007/BF01276464", "8748672"]}, {"Citation": "Kouti L, Noroozian M, Akhondzadeh S, Abdollahi M, Javadi MR, Faramarzi MA, Mousavi S, Ghaeli P (2013) Nitric oxide and peroxynitrite serum levels in Parkinson\u2019s disease: correlation of oxidative stress and the severity of the disease. Eur Rev Med Pharmacol Sci 17:964\u2013970", "ArticleIdList": ["23640445"]}, {"Citation": "Kuiper MA, Visser JJ, Bergmans PLM, Scheltens P, Wolters EC (1994) Decreased cerebrospinal fluid nitrate levels in Parkinson\u2019s disease, Alzheimer\u2019s disease and multiple system atrophy patients. J Neurol Sci 121:46\u201349. https://doi.org/10.1016/0022-510x(94)90155-4", "ArticleIdList": ["10.1016/0022-510x(94)90155-4", "8133311"]}, {"Citation": "L\u00f3pez IC, Ruiz PJG, Del Pozo SVF, Bernardos VS (2010) Motor complications in Parkinson\u2019s disease: ten year follow-up study. Mov Disord 25:2735\u20132739. https://doi.org/10.1002/mds.23219", "ArticleIdList": ["10.1002/mds.23219", "20931632"]}, {"Citation": "MacArthur PH, Shiva S, Gladwin MT (2007) Measurement of circulating nitrite and S-nitrosothiols by reductive chemiluminescence. J Chromatogr B Analyt Technol Biomed Life Sci 851:93\u2013105. https://doi.org/10.1016/j.jchromb.2006.12.012", "ArticleIdList": ["10.1016/j.jchromb.2006.12.012", "17208057"]}, {"Citation": "Marchioni C, Santos-Lobato BL, Queiroz MEC, Crippa JAS, Tumas V (2020) Endocannabinoid levels in patients with Parkinson\u2019s disease with and without levodopa-induced dyskinesias. J Neural Transm 127:1359\u20131367. https://doi.org/10.1007/s00702-020-02240-9", "ArticleIdList": ["10.1007/s00702-020-02240-9", "32797288"]}, {"Citation": "Medeiros MS, Schumacher-Schuh A, Cardoso AM, Bochi GV, Baldissarelli J, Kegler A, Santana D, Chaves CMMBS, Schetinger MRC, Moresco RN, Rieder CRM, Fighera MR (2016) Iron and oxidative stress in Parkinson\u2019s disease: an observational study of injury biomarkers. PLoS ONE 11:e0146129. https://doi.org/10.1371/journal.pone.0146129", "ArticleIdList": ["10.1371/journal.pone.0146129", "26751079", "4709097"]}, {"Citation": "Molina JA, Jim\u00e9nez-Jim\u00e9nez FJ, Navarro JA, Ruiz E, Arenas J, Cabrera-Valdivia F, V\u00e1zquez A, Fern\u00e1ndez-Calle P, Ayuso-Peralta L, Rabasa M (1994) Plasma levels of nitrates in patients with Parkinson\u2019s disease. J Neurol Sci 127:87\u201389. https://doi.org/10.1016/0022-510x(94)90139-2", "ArticleIdList": ["10.1016/0022-510x(94)90139-2", "7699396"]}, {"Citation": "Molina JA, Jim\u00e9nez-Jim\u00e9nez FJ, Navarro JA, Vargas C, G\u00f3mez P, Benito-Le\u00f3n J, Ort\u00ed-Pareja M, Cisneros E, Arenas J (1996) Cerebrospinal fluid nitrate levels in patients with Parkinson\u2019s disease. Acta Neurol Scand 93:123\u2013126. https://doi.org/10.1111/j.1600-0404.1996.tb00186.x", "ArticleIdList": ["10.1111/j.1600-0404.1996.tb00186.x", "8741130"]}, {"Citation": "Mufson EJ, Brandabur MM (1994) Sparing of NADPH-diaphorase striatal neurons in Parkinson\u02bcs and Alzheimer\u02bcs diseases. NeuroReport 5:705\u2013708. https://doi.org/10.1097/00001756-199402000-00011", "ArticleIdList": ["10.1097/00001756-199402000-00011", "8199342"]}, {"Citation": "Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel EA (2009) Nitric oxide synthase inhibition attenuates l-DOPA-induced dyskinesias in a rodent model of Parkinson\u2019s disease. Neuroscience 159:927\u2013935. https://doi.org/10.1016/j.neuroscience.2009.01.034", "ArticleIdList": ["10.1016/j.neuroscience.2009.01.034", "19302833"]}, {"Citation": "Padovan-Neto FE, Cavalcanti-Kiwiatkoviski R, Carolino ROG, Anselmo-Franci J, Del Bel E (2015) Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. Neuropharmacology 89:87\u201399. https://doi.org/10.1016/j.neuropharm.2014.08.019", "ArticleIdList": ["10.1016/j.neuropharm.2014.08.019", "25196732"]}, {"Citation": "Pav\u00f3n N, Mart\u00edn AB, Mendialdua A, Moratalla R (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59:64\u201374. https://doi.org/10.1016/j.biopsych.2005.05.044", "ArticleIdList": ["10.1016/j.biopsych.2005.05.044", "16139809"]}, {"Citation": "Qureshi GA, Baig S, Bednar I, S\u00f6dersten P, Forsberg G, Siden A (1995) Increased cerebrospinal fluid concentration of nitrite in Parkinson\u2019s disease. NeuroReport 6:1642\u20131644. https://doi.org/10.1097/00001756-199508000-00013", "ArticleIdList": ["10.1097/00001756-199508000-00013", "8527732"]}, {"Citation": "Rejdak K, Petzold A, Sharpe MA, Smith M, Keir G, Stelmasiak Z, Thompson EJ, Giovannoni G (2003) Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury. J Neurol Sci 208:1\u20137. https://doi.org/10.1016/s0022-510x(02)00412-4", "ArticleIdList": ["10.1016/s0022-510x(02)00412-4", "12639718"]}, {"Citation": "Santos-Lobato BLD, Del-Bel E, Pittella JEH, Tumas V (2016) Cytoarchitecture of nitrergic neurons in the human striatum and subthalamic nucleus. Brain Res Bull 124:129\u2013135. https://doi.org/10.1016/j.brainresbull.2016.04.003", "ArticleIdList": ["10.1016/j.brainresbull.2016.04.003", "27060610"]}, {"Citation": "Shukla R, Rajani M, Srivastava N, Barthwal MK, Dikshit M (2006) Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson\u2019s disease. Int J Neurosci 116:1391\u20131402. https://doi.org/10.1080/00207450500513989", "ArticleIdList": ["10.1080/00207450500513989", "17145675"]}, {"Citation": "Tsikas D (2005) Methods of quantitative analysis of the nitric oxide metabolites nitrite and nitrate in human biological fluids. Free Radic Res 39:797\u2013815. https://doi.org/10.1080/10715760500053651", "ArticleIdList": ["10.1080/10715760500053651", "16036360"]}, {"Citation": "Tsikas D (2007) Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the L-arginine/nitric oxide area of research. J Chromatogr B Analyt Technol Biomed Life Sci 851:51\u201370. https://doi.org/10.1016/j.jchromb.2006.07.054", "ArticleIdList": ["10.1016/j.jchromb.2006.07.054", "16950667"]}, {"Citation": "Wei Z, Li X, Li X, Liu Q, Cheng Y (2018) Oxidative stress in Parkinson\u2019s disease: a systematic review and meta-analysis. Front Mol Neurosci 11:236. https://doi.org/10.3389/fnmol.2018.00236", "ArticleIdList": ["10.3389/fnmol.2018.00236", "30026688", "6041404"]}, {"Citation": "Wennmalm A, Benthin G, Edlund A, Jungersten L, Kieler-Jensen N, Lundin S, Westfelt UN, Petersson AS, Waagstein F (1993) Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Circ Res 73:1121\u20131127. https://doi.org/10.1161/01.res.73.6.1121", "ArticleIdList": ["10.1161/01.res.73.6.1121", "8222083"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "9", "Day": "21"}, {"Year": "2021", "Month": "11", "Day": "24"}, {"Year": "2021", "Month": "12", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "3", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "12", "Day": "23", "Hour": "12", "Minute": "53"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34940921", "10.1007/s00702-021-02447-4", "10.1007/s00702-021-02447-4"]}}], "PubmedBookArticle": []}